Charles River Laboratories Inte (CRL) Stock Analysis
Falling Knife setup
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $149.93: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
Charles River Laboratories is a full-service drug development partner serving pharmaceutical and biotech companies through three segments: RMS (21.1% of 2025 revenue), DSA (59.8%), and Manufacturing Solutions (19.1%). Total revenue was $4.0 billion in 2025, with the company... Read more
Sell if holding. Engine safety override at $149.93: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross, below all MAs, RSI 37, MACD bearish. Score 4.9/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Charles River Laboratories Inte
Latest news
- Charles River And MEDIPOST Enter Into Strategic, Non-Exclusive MOU To Collaborate On GMP-Compliant Testing To Advance Ce — benzinga May 13, 2026 positive
- These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results — benzinga May 8, 2026 positive
- Barclays Maintains Overweight on Charles River, Raises Price Target to $220 — benzinga May 8, 2026 positive
- Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $220 — benzinga May 8, 2026 positive
- Charles River Lowers FY2026 Sales Guidance from $3.814B-$3.874B to $3.794B-$3.854B vs $3.935B Est — benzinga May 7, 2026 negative
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliernon-human primate supply10-K Item 1A: 'Several of our product and service offerings, including our non-human primate supply, are dependent on a limited source of supply that, when interrupted, adversely affects our business.'
Material Events(8-K, last 90d)
- 2026-02-18Item 5.02MEDIUMGlenn Coleman appointed as Corporate EVP and CFO with tentative start date April 6, 2026. Joins from Premier, Inc. where he served as CFO and Chief Administrative Officer. Named successor with start date; prior CFO not mentioned.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Unprofitable operations — net margin -4.6%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $149.93: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross, below all MAs, RSI 37, MACD bearish. Prior stop was $144.94. Score 4.9/10, moderate confidence.
Take-profit target: $187.92 (+25.3% upside). Prior stop was $144.94. Stop-loss: $144.94.
Concentration risk — Supplier: non-human primate supply; Quality below floor (3.4 < 4.0).
Charles River Laboratories Inte trades at a P/E of N/A (forward 12.2). TrendMatrix value score: 8.4/10. Verdict: Sell.
24 analysts cover CRL with a consensus score of 3.9/5. Average price target: $209.
What does Charles River Laboratories Inte do?Charles River Laboratories is a full-service drug development partner serving pharmaceutical and biotech companies...
Charles River Laboratories is a full-service drug development partner serving pharmaceutical and biotech companies through three segments: RMS (21.1% of 2025 revenue), DSA (59.8%), and Manufacturing Solutions (19.1%). Total revenue was $4.0 billion in 2025, with the company serving most global pharmaceutical companies and biotechnology clients. It is the largest provider of outsourced non-clinical safety assessment services worldwide.